Research · Sep 3, 2026
[CRSP] CRISPR Therapeutics Thesis 2026: A CRISPR-Cas9 Gene-Editing Pioneer Scales Casgevy Royalty While Pipeline Validates In Vivo Applications
CRISPR Therapeutics AG (NASDAQ: CRSP), headquartered in Zug, Switzerland with operational headquarters in Cambridge, Massachusetts, is a clinical-and-commercial-stage biotech pioneering the development of CRISPR/Cas9-based gene-editing therapies for hematological diseases, oncology, autoimmune, cardiovascular, and regenerative-medicine indications. Founded in 2013 by Emmanuelle Charpentier (the 2020 Nobel Prize in Chemistry laureate for co-discovering CRISPR/Cas9 gene-editing with Jennifer Doudna — one of the most-significant biotechnology discoveries of the past 50 years) and co-founders with Versant Ventures as founding capital partner; IPO'd October 2016 at $14/share. Under President & CEO Sam Kulkarni (since 2022, joined CRISPR Therapeutics 2015, previously at Vertex), FY2025 closes with selected various aggregate revenue ~$50-150M (Casgevy commercial royalties + Vertex collaboration income), net loss ~$200-400M, cash + investments ~$1.6-1.9B (one of strongest cash positions in clinical-stage biotech relative to burn rate providing ~5+ year operating runway), and ~88M shares outstanding. The first deep-dive — the Casgevy commercial program + the Vertex Pharmaceuticals partnership — covers the first FDA-approved CRISPR/Cas9 gene-editing therapy. Casgevy (exagamglogene autotemcel, formerly exa-cel) approved by FDA December 2023 for sickle cell disease + January 2024 for transfusion-dependent beta-thalassemia — the first regulatory approval of a CRISPR/Cas9-based therapy anywhere in the world. Subsequent global approvals in EU, UK, Switzerland, Saudi Arabia, Bahrain through 2024-2025. The mechanism is a one-time autologous ex-vivo gene-editing therapy: collect patient HSCs via apheresis → edit ex-vivo using CRISPR/Cas9 to disable BCL11A (gene repressing fetal hemoglobin) → busulfan conditioning → re-infuse edited HSCs that engraft and express fetal hemoglobin compensating for defective adult hemoglobin. Patients are essentially cured. The Vertex Pharmaceuticals partnership is structurally central — Vertex handles commercial launch + marketing + distribution + manufacturing at Vertex cell-therapy facilities + regulatory/clinical-development; CRISPR Therapeutics receives mid-to-high-single-digit-to-low-double-digit royalty on worldwide Casgevy sales + collaboration revenue. Launch progressing modestly: ~50-200+ patients treated globally, ~75+ authorized treatment centers activated, $2.2M+ list price (one of highest in pharma history). Launch pace structurally slow due to procedure complexity + high price + addressable-population concentration + competitive alternative bluebird bio Lyfgenia for SCD. FY2026 catalyst is Casgevy commercial ramp pace, Vertex partnership execution, ATC activation, payer coverage, and indication expansion. The second deep-dive — the broader CAR-T cell therapy + cardiovascular gene-editing + autoimmune pipeline — covers CRSP's multi-program option-value-creating future-growth pillars. Allogeneic CAR-T cell therapies CTX112 (anti-CD19 for B-cell malignancies + autoimmune lupus/MG/MS) and CTX131 (anti-CD70 for solid tumors + heme malignancies) target the next-generation allogeneic CAR-T thesis — ready-to-use donor-derived CAR-T cells eliminating autologous manufacturing complexity + cost + logistics. The autoimmune-CAR-T category is one of the most exciting recent biotech areas with autologous CAR-T autoimmune-remission data showing dramatic clinical-response signals. In vivo cardiovascular gene editing — CTX320 (in vivo Lp(a) gene editing for cardiovascular risk reduction, ~$50B+ addressable market for Lp(a) lowering as independent CV/aortic-stenosis risk factor affecting ~20%+ of population) and CTX330 — represents the multi-billion-dollar in-vivo-cardiovascular-gene-editing thesis. FY2026 catalyst is CTX112 + CTX131 CAR-T clinical readouts, CTX320 Lp(a) Phase 1 data (dominant in-vivo platform validator), and platform-partnership announcements. Competes with Editas (EDIT), Beam (BEAM), Intellia (NTLA), Verve (VERV direct in-vivo CV comp), Prime Medicine (PRME), Sangamo (SGMO), Allogene (ALLO), Caribou (CRBU), Cellectis (CLLS); Lp(a) competitors Novartis Pelacarsen, Eli Lilly Muvalaplin, Amgen Olpasiran, Silence (SLN), Arrowhead (ARWR). Capital position is net-cash and growth-investment-focused: ~$1.6-1.9B cash (~5+ year runway), near-zero debt, negative FCF ~$200-400M/yr, R&D ~$300-500M/yr, SG&A ~$80-130M/yr, no dividend, modest opportunistic buybacks, SBC ~$80-120M/yr, ~88M shares. At ~$35-65 per share, equity value ~$3.5-6.0B and EV ~$1.7-4.2B (after ~$1.6-1.9B cash adjustment), valuation reflects option-value of diversified pipeline + Casgevy royalty NPV + net-cash cushion. Base case is Casgevy ramp + clinical readouts + moderate return; bull case is CTX320 Lp(a) Phase 1 delivery + CTX112 autoimmune validation + Casgevy acceleration + re-rating to $80-120+ + 50-100%+ return; bear case is pipeline misses + Casgevy stalls + runway concerns + de-rating to $20-30.